BRAF and melanoma: In contrast to the foregoing study that ascribed a pro-oncogenic function to MondoA, evidence for TS-like activity was provided by studies which examined glycolytic rates of melanomas bearing oncogenic B-RafV600E mutations prior to and following treatment with the B-Raf inhibitors vemurafinib and dabrafenib [384].